AtriCure (NSDQ:ATRC) announced today that the FDA approved its EPi-Sense system for treating long-standing persistent atrial fibrillation (Afib). Mason, Ohio-based AtriCure’s EPi-Sense system demonstrated superiority in the Hybrid AF therapy arm compared to endocardial catheter ablation alone in the Converge clinical trial, according to a news release. AtriCure’s Hybrid AF therapy is a minimally invasive […]
AtriCure Inc.
AtriCure names Angie Wirick as chief financial officer
AtriCure (NASDAQ:ATRC) recently announced that it has appointed Angie Wirick as chief financial officer, effective August 6. Wirick, who was VP of finance, replaces Andy Wade who is stepping down for personal reasons and will continue to serve in an advisory role through March 5, 2021. “On behalf of our team at AtriCure and our Board […]
AtriCure to raise $100m from public offering
AtriCure (NASDAQ:ATRC) said today that it commenced a public offering to issue and sell roughly $100 million worth of its common stock. The Mason, Ohio–based company — maker of treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management — said it plans to grant the underwriters of the offering a 30-day option to […]
These 10 medtech companies care a lot about research
These 10 medical device companies spent the largest portion of their budgets on research and development. Here’s a look at what they produced. Each year, Medical Design & Outsourcing compiles a list of the top 100 medical device companies across the globe and ranks the companies based on annual revenue for the most recent fiscal year. We […]
AtriCure wins expanded indications for AtriClip LAA
AtriCure (NSDQ:ATRC) said today that it won expanded 510(k) clearances from the FDA for its AtriClip left atrial appendage device. The new indications cover a change from occlusion of the LAA to exclusion and adding electrical isolation as a claim, Mason, Ohio-based AtriCure said. AtriClip excludes the LAA and causes its tissue to die from loss […]
AtriCure closes $300m SentreHeart buyout
AtriCure (NSDQ:ATRC) said yesterday that it closed the $300 million buyout of SentreHeart and its Lariat left atrial appendage closure device. The offer included $40 million in up-front cash and stock, plus $140 million in clinical and regulatory milestones and $120 million in reimbursement milestones, all payable in cash and stock, Mason, Ohio-based AtriCure said when the […]
AtriCure offers $300m for SentreHeart
AtriCure (NSDQ:ATRC) said today that it put up a $300 million offer for SentreHeart and its Lariat left atrial appendage closure device. Redwood City, Calif.-based SentreHeart has enrolled 535 patients in the Amaze trial comparing Lariat and pulmonary vein isolation with PVI alone in treating atrial fibrillation. Today AtriCure said it expects the study tor each […]
AtriCure shares steady on Street-beating Q1
Shares in AtriCure (NSDQ:ATRC) are steady in after hours trading today after the medical device maker posted first quarter earnings for 2019 that beat expectations on Wall Street. The Mason, Ohio-based company posted losses of approximately $5.6 million, or 15¢ per share, on sales of approximately $54 million for the three months ended March 31, seeing […]
AtriCure restarts DEEP dual-procedure clinical trial
AtriCure (NSDQ:ATRC) said today that it restarted enrollment in its DEEP clinical trial, touting that the first newly added patient in the trial has already been treated. The Mason, Ohio-based company’s DEEP trial is an FDA investigational device exempt study exploring the safety and efficacy of the company’s dual epicardial and endocardial procedure intended to treat […]
AtriCure shares dip despite Q4 earnings beat
Shares in AtriCure (NSDQ:ATRC) have fallen slightly today despite the medical device maker posting fourth quarter earnings that topped expectations on Wall Street. The Mason, Ohio-based company posted losses of $3.4 million, or 9¢ per share, on sales of $52.9 million for the three months ended December 31, seeing losses grow 32.9% while sales grew 14.8% […]
AtriCure launches CryoIce CryoSphere probe
AtriCure (NSDQ:ATRC) today launched its CryoIce CryoSphere probe in the U.S. The Mason, Ohio-based company’s CryoSphere probe is designed to block pain by temporarily ablating peripheral nerves. The device features a bendable distal shaft and an ergonomic handle that enables cardiac, thoracic and general surgeons to easily target peripheral nerves. ArtiCure’s CryoSphere technology uses a freezing […]
